Company Description
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
The company’s products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer’s disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson’s disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders.
The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019.
MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 27, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Christopher Kroeger |
Contact Details
Address: 800 Chesapeake Drive Redwood City, California 94063 United States | |
| Phone | 617 984 6300 |
| Website | maplightrx.com |
Stock Details
| Ticker Symbol | MPLT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001770069 |
| CUSIP Number | 56565P103 |
| ISIN Number | US56565P1030 |
| Employer ID | 83-2163243 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher A. Kroeger, M.D. | Chief Executive Officer and Director |
| Vishwas Setia | Chief Financial Officer |
| Erin Pennock Foff, M.D., Ph.D. | Chief Medical Officer |
| Jonathan Gillis | Chief Administrative and Accounting Officer |
| Anatol Kreitzer, Ph.D. | Chief Discovery Officer |
| James Lillie, Ph.D. | Chief Scientific Officer |
| Kristopher L. Hanson | General Counsel |
| Timothy Garnett, M.B.B.S. | Director |
| Nanna Lüneborg, Ph.D. | Director |
| Robert Malenka, M.D., Ph.D | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 4, 2025 | 10-Q | Quarterly Report |
| Dec 4, 2025 | 8-K | Current Report |
| Nov 20, 2025 | SCHEDULE 13D | Filing |
| Nov 4, 2025 | SCHEDULE 13D | Filing |
| Oct 29, 2025 | 8-K | Current Report |
| Oct 27, 2025 | 424B3 | Prospectus |
| Oct 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 27, 2025 | FWP | Free Writing Prospectus |
| Oct 24, 2025 | CERT | Certification by an exchange approving securities for listing |
| Oct 24, 2025 | 8-A12B | Registration of securities |